Pacific Biosciences
Leading provider of long-read sequencing platforms that enable researchers and clinicians to comprehensively characterize genetic variation, including complex structural variants and epigenetic modifications.
Website
https://www.pacb.comLocation
Menlo Park, California, USA
Founded
2004
Investors
1
Categories
genomics-sequencing, biotech, diagnostics, long-read-sequencing
Notes
Pacific Biosciences (PacBio) is a leading provider of long-read, highly accurate sequencing solutions. The company's Single Molecule, Real-Time (SMRT) sequencing technology enables researchers to generate complete and accurate genome assemblies, detect epigenetic modifications, and characterize complex genetic variations.
PacBio's platforms, including the Sequel IIe and Revio systems, are used in research, clinical, and applied markets for applications ranging from human genetics to infectious disease surveillance.
Team
- Christian Henry - Chief Executive Officer
- LinkedIn: linkedin.com/in/christianhenry
- Mark Van Oene - President & Chief Commercial Officer
Additional Research Findings
- Founded in 2004 in Menlo Park, California
- Listed on NASDAQ (ticker: PACB)
- Pioneer in long-read SMRT sequencing technology
- Products include Sequel II/IIe and Revio platforms
- HiFi (high-fidelity) reads combine long read length with high accuracy
- Applications in de novo genome assembly, structural variant detection
- Complements short-read technologies like Illumina
- Used in clinical genomics, cancer research, and pathogen detection
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Alloy Ventures | Palo Alto, USA | generalist | seedseries-a+1 | 1 |